Drug intelligence / Profile preview

NHI-2

Development stage: Preclinical
Lead developer: University of Pisa
Modality: Small Molecules
Administration: In Vitro (preclinical Data; Not Approved For Human Use)

Overview

NHI-2 is a **small molecule inhibitor** of the enzyme **lactate dehydrogenase A (LDHA)**, designed to directly target cancer cell metabolism. It reduces lactate production in various cancer cell lines, including HeLa, LPC006, and PANC-1, by inhibiting LDHA activity. Preclinical studies have shown that NHI-2 disrupts glycolysis, decreases cellular ATP and NADH/NAD+ ratio, and inhibits cancer cell growth. It is particularly cytotoxic against pancreatic cancer cell lines and has been found to enhance the antitumor activity of gemcitabine in vitro. NHI-2 may also inhibit ferroptosis. The compound is under investigation as an antineoplastic agent but is not yet in clinical development[3][1].

Targets

LDH (L-lactate dehydrogenase A chain)

Beyond the preview

Go deeper on NHI-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NHI-2.

Explore the full profile